Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
LabCorp (LH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.
Quidel's (QDEL) Antigen Tests Successful in Omicron Detection
by Zacks Equity Research
The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.
PacBio's (PACB) New Surveillance Kit Successful Against Omicron
by Zacks Equity Research
PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients
by Zacks Equity Research
Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.
LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Quest Diagnostics (DGX) and LabCorp (LH) have performed compared to their sector so far this year.
LH vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm
by Zacks Equity Research
Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.
5 Momentum Stocks Bargain Hunters Would Love Chasing
by Sandip Chakraborty
Given the prevailing sentiment in the market, Academy Sports (ASO), Avis Budget (CAR), Laboratory Corporation (LH), Penske Automotive (PAG) and West Fraser (WFG) are expected to give handsome returns to momentum investors.
Hologic (HOLX) to Meet High Testing Demand With Panther Trax
by Zacks Equity Research
Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.
BD's (BDX) Latest Buyout to Enhance its Digital Capabilities
by Zacks Equity Research
BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.
Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome
by Zacks Equity Research
Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
Integra (IART) Businesses Rebound Despite Supply Issues
by Zacks Equity Research
Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.
Medtronic (MDT) Businesses Rebound Amid Raging Pandemic
by Zacks Equity Research
Medtronic (MDT) is registering strong organic growth in the Cardiovascular, Neuroscience and Diabetes segments on product launches.
Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Retain Haemonetics (HAE) Stocks for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.